<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Bhutani, Surabhi</dc:creator>
  <dc:creator>Coppin, Géraldine</dc:creator>
  <dc:creator>Veldhuizen, Maria Geraldine</dc:creator>
  <dc:creator>Parma, Valentina</dc:creator>
  <dc:creator>Joseph, Paule Valery</dc:creator>
  <dc:date>2021-03-02</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">&lt;jats:title&gt;Abstract&lt;/jats:title&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Background/objectives&lt;/jats:title&gt;&lt;jats:p&gt;Individuals with obesity show alterations in smell and taste abilities. Smell and taste loss are also the most prominent neurological symptoms of COVID-19, yet how chemosensory ability present in individuals with obesity with a positive COVID-19 diagnosis is unknown.&lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Subjects/Methods&lt;/jats:title&gt;&lt;jats:p&gt;In this secondary analysis of a cross-sectional global dataset, we compared self-reported chemosensory ability in participants with a respiratory illness reporting a positive (C19+; n = 5156) or a negative (C19−; n = 659) COVID-19 laboratory test outcome, who also self-reported to be obese (C19+; n = 433, C19−; n = 86) or non-obese.&lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Results&lt;/jats:title&gt;&lt;jats:p&gt;Compared to the C19− group, C19+ exhibited a greater decline in smell, taste, and chemesthesis during illness, though these symptoms did not differ between participants with obesity and without obesity. In 68% of participants who reported recovery from respiratory illness symptoms (n=3431 C19+ and n= 539 C19−), post-recovery chemosensory perception did not differ in C19+ and C19− diagnosis, and by self-reported obesity. Finally, we found that all chemosensory and other symptoms combined predicted the C19+ diagnosis in participants with obesity with a moderately good estimate (63% accuracy). However, in C19+ participants with obesity, we observed a greater relative prevalence of non-chemosensory symptoms, including respiratory as respiratory and GI symptoms.&lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Conclusions&lt;/jats:title&gt;&lt;jats:p&gt;We conclude that despite a presumed lower sensitivity to chemosensory stimuli, COVID-19 respondents with obesity experience a similar self-reported chemosensory loss as those without obesity, and in both groups self-reported chemosensory symptoms are similarly predictive of COVID-19.&lt;/jats:p&gt;&lt;/jats:sec&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.unidistance.ch/global/documents/336001</dc:identifier>
  <dc:identifier>https://n2t.net/ark:/51647/srd1336001</dc:identifier>
  <dc:identifier>https://sonar.unidistance.ch/documents/336001/files/COVID-19-Related-Chemosensory-Changes-in-Individuals-with-Self-Reported-Obesity.pdf</dc:identifier>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1101/2021.02.28.21252536</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/51647/srd1336001</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Rhinology. - 2021</dc:source>
  <dc:title xmlns:ns1="xml" ns1:lang="en">COVID-19 Related Chemosensory Changes in Individuals with Self-Reported Obesity</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_816b</dc:type>
</oai_dc:dc>
